FDA Panel Points to Narrower Label for Amgen's (AMGN) Repatha, Nomura Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cowen Maintains Bullish View on Amgen (AMGN) Following Panel Repatha In Familial Hypercholesterolemia
June 11, 2015 7:13 AM EDTCowen analyst Eric Schmidt reiterating an Outperform rating and $189 price target on Amgen (NASDAQ: AMGN) after an FDA panel backed Repatha in familial hypercholesterolemia.
Analyst Erich Schmidt commented, "The FDA's EMDAC panel recommended Repatha be approved for HoFH (15:0 vote) and one more additional very... More
Amgen (AMGN) Bullish Stance Reiterated at Jefferies Following Repatha Panel Backing
June 11, 2015 6:43 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and $195 price target on Amgen (NASDAQ: AMGN) after an FDA panel recommended approval of Repatha, as expected.
Yang commented, "Positive panel votes were widely expected (11-4 in favor for non-HoFH high-risk pts;... More
After-Hours Stock Movers 06/10: (BOX) (KKD) (MW) Higher; (DRNA) (FOLD) (BBG) Lower (more...)
June 10, 2015 6:01 PM EDTBox (NYSE: BOX) 8.7% HIGHER; reported Q1 EPS of ($0.28), $0.03 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $63.7 million. Q2 revenue is expected to be in the range of $69 to $70 million, versus the consensus of $67 million. FY16 revenue is expected to be in the range of $286 to $290 million, compared to previous guidance of $281 to $285 million and the consensus of $283 million.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) 5.5% LOWER; Alnylam Pharma... More
UPDATE: Amgen (AMGN) Wins FDA Panel Backing for Repatha
June 10, 2015 3:57 PM EDT(Updated - June 10, 2015 4:26 PM EDT)
An FDA panel voted 11-4 to back Amgen's (NASDAQ: AMGN) Repatha in some patients. The panel also backed the drug for HoFH with a vote of 15-0.
Repatha is an investigational fully human monoclonal antibody that inhibits... More
